Ron Firestein, Ph.D.
Affiliations: | 2002 | Stanford University, Palo Alto, CA |
Area:
ToxoplasmaGoogle:
"Ron Firestein"Parents
Sign in to add mentor| Michael D. Cleary | grad student | 2002 | Stanford | |
| (Molecular and genetic characterization of the roles of the Sbf1 pseudo-phosphatase in growth control and development.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Sun CX, Daniel P, Bradshaw G, et al. (2023) Generation and multi-dimensional profiling of a childhood cancer cell line atlas defines new therapeutic opportunities. Cancer Cell |
| Dicara DM, Bhakta S, Go MA, et al. (2022) Development of T-cell engagers selective for cells co-expressing two antigens. Mabs. 14: 2115213 |
| Sooraj D, Sun C, Doan A, et al. (2021) MED12 and BRD4 cooperate to sustain cancer growth upon loss of mediator kinase. Molecular Cell |
| Daemen A, Liu B, Song K, et al. (2018) Pan-Cancer Metabolic Signature Predicts Co-Dependency on Glutaminase and De Novo Glutathione Synthesis Linked to a High-Mesenchymal Cell State. Cell Metabolism |
| Raab M, Sanhaji M, Matthess Y, et al. (2018) PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells. Nature Communications. 9: 1106 |
| Bhakta S, Crocker LM, Chen Y, et al. (2017) An anti-GDNF Family Receptor Alpha 1(GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer. Molecular Cancer Therapeutics |
| Mahara S, Firestein R. (2017) Targeting the seeds of small cell lung cancer. Annals of Translational Medicine. 5: 113 |
| Liu JF, Moore KN, Birrer MJ, et al. (2016) Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 27: 2124-2130 |
| Terwisscha van Scheltinga AG, Ogasawara A, Pacheco G, et al. (2016) Preclinical Efficacy of an Antibody-Drug Conjugate Targeting Mesothelin Correlates with Quantitative 89Zr-ImmunoPET. Molecular Cancer Therapeutics |
| Boudreau A, Purkey HE, Hitz A, et al. (2016) Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition. Nature Chemical Biology |